N-(2-chlorophenyl)-2-(1H-indol-3-yl)-2-oxoacetamide | 852367-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(2-chlorophenyl)-2-(1H-indol-3-yl)-2-oxoacetamide
• CAS: 852367-66-9
• 化学式: C₁₆H₁₁ClN₂O₂
• mdl: MFCD00533115
• 分子量: 298.729
• InChiKey: NLYRDFJCBHZFBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吲哚 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 3.25h， 生成 N-(2-chlorophenyl)-2-(1H-indol-3-yl)-2-oxoacetamide
  参考文献：
  名称：

  One-pot three-component synthesis of indole-3-glyoxyl derivatives and indole-3-glyoxyl triazoles

  摘要：

  A general and efficient reaction of indole with oxalyl chloride and nucleophiles providing indole-3-glyoxyl derivatives has been developed in mild conditions. In the same fashion, the other reaction involved the addition of organic azides leading to the synthesis of indole-3-glyoxyl-1,2,3-triazoles, which proceeds smoothly generating the products in moderate to high yields. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.08.064

文献信息

• Design, Synthesis, and Structure−Activity Relationship of Indole-3-glyoxylamide Libraries Possessing Highly Potent Activity in a Cell Line Model of Prion Disease
  作者：Mark J. Thompson、Vinciane Borsenberger、Jennifer C. Louth、Katie E. Judd、Beining Chen

  DOI：10.1021/jm900920x

  日期：2009.12.10

  curative therapy currently exists. We report here the synthesis of a library of indole-3-glyoxylamides and their evaluation as potential antiprion agents. A number of compounds demonstrated submicromolar activity in a cell line model of prion disease together with a defined structure−activity relationship, permitting the design of more potent compounds that effected clearance of scrapie in the low nanomolar

  传染性海绵状脑病（TSE）是一类致命的神经退行性疾病，目前尚无有效的治疗方法。我们在这里报告了吲哚-3-乙二酰胺的文库的合成及其作为潜在的抗evaluation剂的评估。许多化合物在pr病毒疾病的细胞系模型中表现出亚微摩尔活性，并具有确定的结构-活性关系，从而可以设计出更有效的化合物，从而在低纳摩尔范围内实现对瘙痒病的清除。因此，本文所述的吲哚-3-乙氧基乙酰胺构成了理想的候选物，以进一步发展成为人类病毒病家族的潜在治疗剂。
• Compounds that enhance Atoh-1 expression
  申请人：MASSACHUSETTS EYE & EAR INFIRMARY

  公开号：EP2732819A2

  公开（公告）日：2014-05-21

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g. a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中 Atoh1 基因（如 Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• Compounds that enhance Atoh1 expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US10406163B2

  公开（公告）日：2019-09-10

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中Atoh1基因（如Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如，与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• Efficient delivery of therapeutic molecules to cells of the inner ear
  申请人：Massachusetts Eye and Ear Infirmary

  公开号：US11370823B2

  公开（公告）日：2022-06-28

  Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

  提供了诱导内耳细胞进入细胞周期和增殖的组合物。特别是，通过服用能激活 Myc 和 Notch 的组合物来诱导毛细胞增殖。通过抑制 Myc 和 Notch 的活性或激活 Atoh1，诱导支持细胞向毛细胞转分化。治疗方法包括在细胞内将这些分子输送到特定的治疗靶点。
• COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：EP2254572A2

  公开（公告）日：2010-12-01